Conversely, BT patients showed a distinct cytokine profile characterized by significantly reduced levels of IFN-γ, IL-2, IL-17F, and IL-22 compared to UT patients, highlighting the potent immune-modulating effects of biological treatments in attenuating pro-inflammatory pathways in psoriasis [26]. The gene discussed is IL22; the disease is psoriasis.